Immune-related hallmark pathway heterogeneity identifies a prognostic risk signature with independent external validation in glioblastoma

Ahmed M. Abdelmaguid, Rasha M. A. Eltanany, Manal F. El-Khadragy, Ahmed E. Abdel Moneim

Open source

DOI: 10.1007/s12672-026-05696-5
Published: 9
Container: Discover Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s12672-026-05696-5,
  title = {Immune-related hallmark pathway heterogeneity identifies a prognostic risk signature with independent external validation in glioblastoma},
  author = {Ahmed M. Abdelmaguid and Rasha M. A. Eltanany and Manal F. El-Khadragy and Ahmed E. Abdel Moneim},
  year = {2026},
  journal = {Discover Oncology},
  doi = {10.1007/s12672-026-05696-5},
  url = {https://doi.org/10.1007/s12672-026-05696-5}
}

RIS

TY  - JOUR
TI  - Immune-related hallmark pathway heterogeneity identifies a prognostic risk signature with independent external validation in glioblastoma
AU  - Ahmed M. Abdelmaguid
AU  - Rasha M. A. Eltanany
AU  - Manal F. El-Khadragy
AU  - Ahmed E. Abdel Moneim
PY  - 2026
JO  - Discover Oncology
DO  - 10.1007/s12672-026-05696-5
UR  - https://doi.org/10.1007/s12672-026-05696-5
ER  -

APA

Abdelmaguid, A. M., Eltanany, R. M. A., El-Khadragy, M. F., & Moneim, A. E. A. (2026). Immune-related hallmark pathway heterogeneity identifies a prognostic risk signature with independent external validation in glioblastoma. Discover Oncology. https://doi.org/10.1007/s12672-026-05696-5

Source records

doaj · retrieved 2026-09-26T00:35:40.826Z